Hemab, still playing coy, gets its first major fundraise for hemophilia bispecifics

A company seeded by Novo’s incubator at the end of 2020 is taking its next step Thursday, emerging into the hemophilia space with a hefty Series A.

The Danish biotech Hemab is putting the bow on a $55 million round early Thursday, raised with money from Novo Seeds as well...

Click to view original post